What are the key additions to the new NCCN guidelines for multiple myeloma? episode artwork

EPISODE · Apr 7, 2021 · 14 MIN

What are the key additions to the new NCCN guidelines for multiple myeloma?

from Multiple Myeloma Hub

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma?Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it’s precursor stages, and changes to treatment regimens for newly diagnosed and relapsed MM. Callander also describes an important update for the recommendation of the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone for the treatment of amyloidosis, providing supporting data from the phase III ANDROMEDA trial. They finish by discussing risk stratification and treatment intervention updates for smoldering MM. Hosted on Acast. See acast.com/privacy for more information.

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma?Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it’s precursor stages, and changes to treatment regimens for newly diagnosed and relapsed MM. Callander also describes an important update for the recommendation of the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone for the treatment of amyloidosis, providing supporting data from the phase III ANDROMEDA trial. They finish by discussing risk stratification and treatment intervention updates for smoldering MM. Hosted on Acast. See acast.com/privacy for more information.

NOW PLAYING

What are the key additions to the new NCCN guidelines for multiple myeloma?

0:00 14:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Multiple Myeloma Hub?

This episode is 14 minutes long.

When was this Multiple Myeloma Hub episode published?

This episode was published on April 7, 2021.

What is this episode about?

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are...

Can I download this Multiple Myeloma Hub episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!